Therefore, if the causal role of PATZ1 in the downregulation of tumor PD-L1 expression is confirmed, future work should investigate the possibility that targeting PATZ1 could enhance the efficacy of anti-PD-1/PD-L1 immunotherapy for NSCLC. This evidence concerns the gene PATZ1 and non-small cell lung carcinoma.